-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3221 Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Clinical Allogeneic Transplantation: Results
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Lakshmikanth Katragadda, MD1, Maxim Norkin, MD, PhD1, Myron Chang, PhD2*, Yunfeng Dai, PhD3*, Jan S Moreb, MD1, W. Stratford May, MD, PhD1, Christopher R. Cogle, MD1, Helen Leather, BPharm1, Ying Li, MD, PhD4*, Lamis K Eldjerou, MD1, John W Hiemenz, MD1*, Randy A. Brown, MD1 and John R. Wingard, MD5

1University of Florida, Gainesville, FL
2Department of Biostatistics, College of Medicine, University of Florida, Gainesville, FL
3Biostatistics, University of Florida, Gainesville, FL
4Pathology, Immunoolgy and Laboratory Medicine, University of Florida, Gainesville, FL
5UF Shands Cancer Center, University of Florida, Gainesville, FL

Introduction: Persistent AML is a known risk factor for poor outcomes after allo-HCT. The impact of MRD in patients who achieve complete remission (CR) or CR with incomplete count recovery (CRi) has been less well studied. 

Methods: We retrospectively reviewed the records of AML patients who underwent allo-HCT in morphological remission (<5% myeloblasts and normal marrow cellularity) with or without blood count recovery between January, 2000 and January, 2014. Data was collected for variables known to impact the prognosis of AML patients (Table 1). MRD was defined as evidence of abnormalities associated with AML by either flow cytometry, cytogenetics or Fluorescence in situ hybridization (FISH). The impact of MRD identified at the time of allo-HCT on cumulative incidence of relapse (CIR), progression free survival (PFS), and overall survival (OS) was assessed in MRD+ and MRD- patients.

Results:  A total of 166 eligible patients were identified. The median follow-up among living patients is 46 months (range, 13–103).Thirty seven (22%) patients had evidence of MRD (13 by flow cytometry only, 17 by cytogenetics/FISH only and 7 by both). MRD was more common in patients with poor risk karyotype at diagnosis and CRi at the time of allo-HCT (Table 1). PFS (P= 0.0016), OS (P=0.002), and CIR (P=0.02) were all significantly worse in MRD+ patients (Figures 1& 2). In univariate analysis, MRD+ patients, assessed by flow cytometry had worse PFS (P=0.0216) and OS (P=0.0314) compared to MRD- patients. Similarly patients with evidence of MRD+ by cytogenetics/FISH had worse PFS (P=0.007) and OS (P=0.0031).  In a multivariate cox proportional hazards model 1) any MRD positivity prior to allo-HCT, 2) poor-risk karyotype at diagnosis, and 3) CRi at allo-HCT independently predicted significantly poor PFS and OS. Only poor-risk karyotype was associated with a significant increase in CIR, while MRD positivity showed a trend towards higher CIR.

Conclusion: MRD positivity prior to HCT by either flow cytometry or by cytogenetics/FISH independently predicts adverse AML outcomes.

 

Table 1: Comparison of pre-transplant variables

Covariate

Label

MRD +

(N=37)

MRD –

(N=129)

P-Value

Age(years)

< 40

8 (21%)

20 (16%)

0.708

40 - 59

20 (53%)

69 (54%)

≥ 60

10 (26%)

39 (30%)

Karyotype risk

Favorable/

Intermediate

19 (53%)

95 (74%)

0.011

Poor

18 (47%)

33 (26%)

Timing of Allo-HCT

1st remission (CR1)

28 (74%)

97 (76%)

0.792

> CR1

10 (26%)

31 (24%)

Allo-HCT after1st  relapse(>CR1): duration of CR1

> 12 mo

31 (82%)

113 (88%)

0.285

≤ 12 mo

7 (18%)

15 (12%)

Secondary AML

No

23 (60%)

78 (61%)

0.964

Yes

15 (40%)

50 (39%)

Complete remission  vs CRi

CR

28 (74%)

110 (86%)

0.077

CRi

10 (26%)

18 (14%)

Conditioning Regimen

Ablative

24 (63%)

72 (56%)

0.449

Other

14 (37%)

56 (44%)

Donor Type

 Matched

sibling donor 

12 (32%)

42 (33%)

0.887

Other

26 (68%)

86 (67%)

Female donor: male recipient (FDMR)

Other

28 (80%)

91 (78%)

0.844

FDMR

7 (20%)

25 (22%)

 

 

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH